Actinium Pharmaceuticals, Inc.

AMEX:ATNM

Biotechnology

Healthcare
$1.64 +15.94%

+$0.22 today

Market cap
$51.56M
Beta
0.02
P/E (TTM)
4.4
EPS (TTM)
$0.36
52W Low $0.74High $1.74

Volume 0.18M

Average 0.15M

ATNM Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Actinium Pharmaceuticals, Inc.AMEX: ATNM

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin at 100.0%

Gross margin was 100.0% in Q2 FY2026. On a trailing-twelve-month basis it was 101.1%. Over 3 fiscal years it widened by 0.0 pp.

Context

  • Gross margin widened in 0 of the last 2 fiscal years.
  • FY2025 was the highest level in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
100.0%— QoQ
Last fiscal yearDec 2025
100.0%— YoY
LTMJun 2026
101.1%— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years+0.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
—

Gross Margin vs competitors

How ATNM compares with its peers on the latest reported figures

  • ATNM's LTM Jun 2026 gross margin of 101.1% is the highest of the 2 companies compared; the peer median is 70.7%.
ATNM Competitors Peer median
Gross Margin for ATNM and competitors
Company Period LTM level YoY 3-year change
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026101.1% —+0.0 pp
XLOXilio Therapeutics, Inc.LTM Mar 202670.7% -29.3 pp—
OKUROnKure Therapeutics, Inc.FY2025— ——
PDSBPDS Biotechnology CorporationFY2025— ——
ANVSAnnovis Bio, Inc.FY2025— ——
Peer median (excluding ATNM) 70.7%-29.3 pp—

Competitors are the stored peer set for ATNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.14M1.03M81K090K
Cost of Revenue524K00811K0
Gross Profit620K1.03M81K(811K)90K
Gross Margin54.2%100.0%100.0%—100.0%
Research & Development17.51M23.14M38.67M30.05M21.12M
Selling, General & Admin8.08M12M13.33M12.08M15.21M
Operating Expenses25.58M35.13M52M41.31M36.34M
Depreciation & Amortization524K699K790K811K821K
EBITDA(24.25M)(32.32M)(48.03M)(37.43M)(33.07M)
EBITDA Margin-2119.8%-3137.7%-59293.8%—-36740.0%
Operating Income(24.96M)(34.1M)(51.92M)(42.12M)(36.25M)
Operating Margin-2182.2%-3311.1%-64098.8%—-40274.4%
Interest Income190K1.09M3.1M3.88M2.36M
Interest Expense00000
Other Income / Expenses190K1.09M3.1M3.88M2.36M
Income Before Tax(24.77M)(33.02M)(48.82M)(38.24M)(33.89M)
Pre-Tax Margin-2165.6%-3205.5%-60269.1%—-37652.2%
Income Tax Expense00000
Net Income(24.77M)(33.02M)(48.82M)(38.24M)(33.89M)
Net Margin-2165.6%-3205.5%-60269.1%—-37652.2%
EPS (Basic)(1.20)(1.37)(1.83)(1.27)(1.09)
EPS (Diluted)(1.20)(1.37)(1.83)(1.27)(1.09)
Weighted Avg Shares20.57M24.14M26.6M30.07M31.2M
Weighted Avg Shares (Diluted)20.57M24.14M26.6M30.07M31.2M

Actinium Pharmaceuticals, Inc.

AMEX:ATNM

Intrinsic Alpha fair value

Locked

Current Price

$1.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.